首頁 > 市場調查報告書 > 製藥

非專利藥生技仿製藥

市場調查報告書

商品編碼

1922434

日本生物相似藥市場報告：按分子、適應症、生產類型和地區分類（2026-2034年）

Japan Biosimilar Market Report by Molecule, Indication, Manufacturing Type, and Region 2026-2034

出版日期: 2026年01月01日 | 出版商:

IMARC | 英文 115 Pages | 商品交期: 5-7個工作天內

價格

簡介目錄

2025年，日本生物相似藥市場規模達5.838億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到36.196億美元，2026年至2034年的複合年成長率將達到22.47%。推動市場成長的關鍵因素包括慢性病盛行率的上升、政府簡化核准流程的措施、老齡化社會的需求、製藥公司的積極參與、成本控制措施、公眾意識的提高以及產品平臺的不斷擴展。

生物相似藥是一種與已已通過核准的參考生物藥高度相似，且無臨床意義差異的生物製品。與學名藥品牌藥的完全相同的複製品）不同，生物相似藥是生物來源的複雜大分子，例如蛋白質或抗體。生物相似藥的研發涉及對生物製劑與參考生物藥的結構、功能和療效進行全面比較。儘管生物製藥固有的複雜性使得生產完全複製品是不可能的，但透過嚴格的測試和監管核准流程，生物相似藥已被證明在安全性和療效方面與參考生物藥高度相似。生物相似藥為昂貴的生物製藥製劑提供了更經濟實惠的替代方案，並在全球範圍內日益受到重視，成為應對醫療成本不斷上漲的一種手段，為醫療系統、醫護人員和患者提供經濟有效的治療選擇，同時又不影響療效。

日本生物相似藥市場趨勢：

癌症和糖尿病等慢性疾病的日益增多，使得人們迫切需要經濟有效的治療方案，這是推動日本生物相似藥市場成長的主要動力。因此，日本政府大力推廣生物相似藥的使用，並引入加快核准流程的法規結構，顯著促進了市場成長。此外，人口老化也推動了對包括生物相似藥在內的經濟型醫療保健解決方案的需求，進一步刺激了市場成長。同時，許多老牌製藥公司大力投資生物相似藥的研發，也推動了市場成長。這些公司正利用自身的專業知識和資源，加速生物相似藥的生產和商業化。此外，國內外製藥公司之間廣泛的合作與夥伴關係，促進了創新，並拓展了生物相似藥的產品範圍，進一步促進了市場成長。此外，受經濟因素驅動，醫療保健行業致力於控制醫療成本，這為日本生物相似藥市場提供了支持，使其成為在不影響療效的前提下顯著降低成本的有效途徑。此外，醫療專業人員和患者對生物相似藥的認知度和接受度不斷提高，正在促進人們對這些替代療法的積極看法，為市場擴張提供了廣泛的機會。同時，對個人化醫療和標靶治療的日益重視，以及涵蓋多個治療領域的生物相似藥產品線的不斷擴展，也為市場成長創造了積極的前景。

本報告解答的關鍵問題

日本生物相似藥市場目前發展狀況如何？您認為未來幾年它將如何發展？
新冠疫情對日本生物相似藥市場產生了哪些影響？
日本生物相似藥市場按分子類型分類的市場組成為何？
日本生物相似藥市場依適應症分類的情況如何？
日本生物相似藥市場依生產方法分類的市場組成為何？
請介紹日本生物相似藥市場價值鏈的各個環節。
日本生物相似藥市場的主要促進因素和挑戰是什麼？
日本生物相似藥市場的結構是怎麼樣的？主要參與者有哪些？
日本生物相似藥市場競爭有多激烈？

Japan biosimilar market size reached USD 583.8 Million in 2025 . Looking forward, IMARC Group expects the market to reach USD 3,619.6 Million by 2034 , exhibiting a growth rate (CAGR) of 22.47% during 2026-2034 . The increasing chronic disease prevalence, government initiatives for streamlined approvals, aging population demands, strong pharmaceutical company involvement, cost containment efforts, heightened awareness, and expanding product pipelines represent some of the key factors driving the market.

Access the full market insights report Request Sample

A biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing, already approved reference biologic drug. Compared to generic versions of small-molecule drugs, which are identical replicas of their branded counterparts, biosimilars are large, complex molecules derived from living organisms, such as proteins or antibodies. The development of biosimilars involves a comprehensive comparison with the reference biologic, encompassing aspects like structure, function, and efficacy. Due to the inherent complexity of biologics, it is impossible to produce exact replicas; however, biosimilars are demonstrated to be highly similar in terms of safety and efficacy through rigorous testing and regulatory approval processes. Biosimilars offers a more affordable alternative to expensive biological drug and have gained prominence globally as a means to address the rising costs of healthcare, providing healthcare systems, practitioners, and patients with cost-effective options without compromising therapeutic benefits.

JAPAN BIOSIMILAR MARKET TRENDS:

The increasing prevalence of chronic diseases, such as cancer and diabetes, necessitating cost-effective treatment options is primarily driving the growth of the Japan biosimilar market. In line with this, the Japanese government's initiatives to promote the use of biosimilars, and the introduction of a regulatory framework to expedite the approval process, are significantly fueling the market growth. Moreover, the rising geriatric population in Japan underscores the demand for affordable healthcare solutions, such as biosimilars, strengthening the market growth. Besides this, the strong presence of established pharmaceutical companies investing in biosimilar research and development (R&D) is providing an impetus to the market growth as these companies leverage their expertise and resources to expedite the production and commercialization of biosimilar products. Concurrently, extensive collaborations and partnerships between domestic and international pharmaceutical firms stimulate innovation and widen the scope of biosimilar offerings, which is contributing to the market's growth. Along with this, the push for healthcare cost containment, driven by economic factors, further bolsters the biosimilar market in Japan, as these products provide an avenue for achieving significant cost savings without compromising on treatment efficacy. Additionally, the increasing awareness and acceptance of biosimilars among healthcare professionals and patients, fostering a positive perception of these alternatives, is presenting lucrative opportunities for the market expansion. Furthermore, the growing emphasis on personalized medicine and targeted therapies and the expanding pipeline of biosimilar products encompassing a diverse range of therapeutic areas are creating a positive outlook for the market growth.

JAPAN BIOSIMILAR MARKET SEGMENTATION:

Molecule Insights:

To get detailed segment analysis of this market Request Sample
Infliximab
Insulin Glargine
Epoetin Alfa
Etanercept
Filgrastim
Somatropin
Rituximab
Follitropin Alfa
Adalimumab
Pegfilgrastim
Trastuzumab
Bevacizumab
Others
Infliximab
Insulin Glargine
Epoetin Alfa
Etanercept
Filgrastim
Somatropin
Rituximab
Follitropin Alfa
Adalimumab
Pegfilgrastim
Trastuzumab
Bevacizumab
Others

Indication Insights:

Auto-Immune Diseases
Blood Disorder
Diabetes
Oncology
Growth Deficiency
Female Infertility
Others
Auto-Immune Diseases
Blood Disorder
Diabetes
Oncology
Growth Deficiency
Female Infertility
Others

Manufacturing Type Insights:

In-House Manufacturing
Contract Manufacturing
In-House Manufacturing
Contract Manufacturing

Regional Insights:

To get detailed regional analysis of this market Request Sample
Kanto Region
Kansai/Kinki Region
Central/ Chubu Region
Kyushu-Okinawa Region
Tohoku Region
Chugoku Region
Hokkaido Region
Shikoku Region
Kanto Region
Kansai/Kinki Region
Central/ Chubu Region
Kyushu-Okinawa Region
Tohoku Region
Chugoku Region
Hokkaido Region
Shikoku Region
The report has also provided a comprehensive analysis of all the major regional markets, which include Kanto Region, Kansai/Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, and Shikoku Region.

COMPETITIVE LANDSCAPE:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

KEY QUESTIONS ANSWERED IN THIS REPORT
How has the Japan biosimilar market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the Japan biosimilar market?
What is the breakup of the Japan biosimilar market on the basis of molecule?
What is the breakup of the Japan biosimilar market on the basis of indication?
What is the breakup of the Japan biosimilar market on the basis of manufacturing type?
What are the various stages in the value chain of the Japan biosimilar market?
What are the key driving factors and challenges in the Japan biosimilar?
What is the structure of the Japan biosimilar market and who are the key players?
What is the degree of competition in the Japan biosimilar market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Biosimilar Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Biosimilar Market Landscape

5.1 Historical and Current Market Trends (2020-2025)
5.2 Market Forecast (2026-2034)

6 Japan Biosimilar Market - Breakup by Molecule

6.1 Infliximab
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2020-2025)
- 6.1.3 Market Forecast (2026-2034)
6.2 Insulin Glargine
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2020-2025)
- 6.2.3 Market Forecast (2026-2034)
6.3 Epoetin Alfa
- 6.3.1 Overview
- 6.3.2 Historical and Current Market Trends (2020-2025)
- 6.3.3 Market Forecast (2026-2034)
6.4 Etanercept
- 6.4.1 Overview
- 6.4.2 Historical and Current Market Trends (2020-2025)
- 6.4.3 Market Forecast (2026-2034)
6.5 Filgrastim
- 6.5.1 Overview
- 6.5.2 Historical and Current Market Trends (2020-2025)
- 6.5.3 Market Forecast (2026-2034)
6.6 Somatropin
- 6.6.1 Overview
- 6.6.2 Historical and Current Market Trends (2020-2025)
- 6.6.3 Market Forecast (2026-2034)
6.7 Rituximab
- 6.7.1 Overview
- 6.7.2 Historical and Current Market Trends (2020-2025)
- 6.7.3 Market Forecast (2026-2034)
6.8 Follitropin Alfa
- 6.8.1 Overview
- 6.8.2 Historical and Current Market Trends (2020-2025)
- 6.8.3 Market Forecast (2026-2034)
6.9 Adalimumab
- 6.9.1 Overview
- 6.9.2 Historical and Current Market Trends (2020-2025)
- 6.9.3 Market Forecast (2026-2034)
6.10 Pegfilgrastim
- 6.10.1 Overview
- 6.10.2 Historical and Current Market Trends (2020-2025)
- 6.10.3 Market Forecast (2026-2034)
6.11 Trastuzumab
- 6.11.1 Overview
- 6.11.2 Historical and Current Market Trends (2020-2025)
- 6.11.3 Market Forecast (2026-2034)
6.12 Bevacizumab
- 6.12.1 Overview
- 6.12.2 Historical and Current Market Trends (2020-2025)
- 6.12.3 Market Forecast (2026-2034)
6.13 Others
- 6.13.1 Historical and Current Market Trends (2020-2025)
- 6.13.2 Market Forecast (2026-2034)

7 Japan Biosimilar Market - Breakup by Indication

7.1 Auto-Immune Diseases
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2020-2025)
- 7.1.3 Market Forecast (2026-2034)
7.2 Blood Disorder
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2020-2025)
- 7.2.3 Market Forecast (2026-2034)
7.3 Diabetes
- 7.3.1 Overview
- 7.3.2 Historical and Current Market Trends (2020-2025)
- 7.3.3 Market Forecast (2026-2034)
7.4 Oncology
- 7.4.1 Overview
- 7.4.2 Historical and Current Market Trends (2020-2025)
- 7.4.3 Market Forecast (2026-2034)
7.5 Growth Deficiency
- 7.5.1 Overview
- 7.5.2 Historical and Current Market Trends (2020-2025)
- 7.5.3 Market Forecast (2026-2034)
7.6 Female Infertility
- 7.6.1 Overview
- 7.6.2 Historical and Current Market Trends (2020-2025)
- 7.6.3 Market Forecast (2026-2034)
7.7 Others
- 7.7.1 Historical and Current Market Trends (2020-2025)
- 7.7.2 Market Forecast (2026-2034)

8 Japan Biosimilar Market - Breakup by Manufacturing Type

8.1 In-House Manufacturing
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2020-2025)
- 8.1.3 Market Forecast (2026-2034)
8.2 Contract Manufacturing
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2020-2025)
- 8.2.3 Market Forecast (2026-2034)

9 Japan Biosimilar Market - Breakup by Region

9.1 Kanto Region
- 9.1.1 Overview
- 9.1.2 Historical and Current Market Trends (2020-2025)
- 9.1.3 Market Breakup by Molecule
- 9.1.4 Market Breakup by Indication
- 9.1.5 Market Breakup by Manufacturing Type
- 9.1.6 Key Players
- 9.1.7 Market Forecast (2026-2034)
9.2 Kansai/Kinki Region
- 9.2.1 Overview
- 9.2.2 Historical and Current Market Trends (2020-2025)
- 9.2.3 Market Breakup by Molecule
- 9.2.4 Market Breakup by Indication
- 9.2.5 Market Breakup by Manufacturing Type
- 9.2.6 Key Players
- 9.2.7 Market Forecast (2026-2034)
9.3 Central/ Chubu Region
- 9.3.1 Overview
- 9.3.2 Historical and Current Market Trends (2020-2025)
- 9.3.3 Market Breakup by Molecule
- 9.3.4 Market Breakup by Indication
- 9.3.5 Market Breakup by Manufacturing Type
- 9.3.6 Key Players
- 9.3.7 Market Forecast (2026-2034)
9.4 Kyushu-Okinawa Region
- 9.4.1 Overview
- 9.4.2 Historical and Current Market Trends (2020-2025)
- 9.4.3 Market Breakup by Molecule
- 9.4.4 Market Breakup by Indication
- 9.4.5 Market Breakup by Manufacturing Type
- 9.4.6 Key Players
- 9.4.7 Market Forecast (2026-2034)
9.5 Tohoku Region
- 9.5.1 Overview
- 9.5.2 Historical and Current Market Trends (2020-2025)
- 9.5.3 Market Breakup by Molecule
- 9.5.4 Market Breakup by Indication
- 9.5.5 Market Breakup by Manufacturing Type
- 9.5.6 Key Players
- 9.5.7 Market Forecast (2026-2034)
9.6 Chugoku Region
- 9.6.1 Overview
- 9.6.2 Historical and Current Market Trends (2020-2025)
- 9.6.3 Market Breakup by Molecule
- 9.6.4 Market Breakup by Indication
- 9.6.5 Market Breakup by Manufacturing Type
- 9.6.6 Key Players
- 9.6.7 Market Forecast (2026-2034)
9.7 Hokkaido Region
- 9.7.1 Overview
- 9.7.2 Historical and Current Market Trends (2020-2025)
- 9.7.3 Market Breakup by Molecule
- 9.7.4 Market Breakup by Indication
- 9.7.5 Market Breakup by Manufacturing Type
- 9.7.6 Key Players
- 9.7.7 Market Forecast (2026-2034)
9.8 Shikoku Region
- 9.8.1 Overview
- 9.8.2 Historical and Current Market Trends (2020-2025)
- 9.8.3 Market Breakup by Molecule
- 9.8.4 Market Breakup by Indication
- 9.8.5 Market Breakup by Manufacturing Type
- 9.8.6 Key Players
- 9.8.7 Market Forecast (2026-2034)

10 Japan Biosimilar Market - Competitive Landscape

10.1 Overview
10.2 Market Structure
10.3 Market Player Positioning
10.4 Top Winning Strategies
10.5 Competitive Dashboard
10.6 Company Evaluation Quadrant

11 Profiles of Key Players

11.1 Company A
- 11.1.1 Business Overview
- 11.1.2 Product Portfolio
- 11.1.3 Business Strategies
- 11.1.4 SWOT Analysis
- 11.1.5 Major News and Events
11.2 Company B
- 11.2.1 Business Overview
- 11.2.2 Product Portfolio
- 11.2.3 Business Strategies
- 11.2.4 SWOT Analysis
- 11.2.5 Major News and Events
11.3 Company C
- 11.3.1 Business Overview
- 11.3.2 Product Portfolio
- 11.3.3 Business Strategies
- 11.3.4 SWOT Analysis
- 11.3.5 Major News and Events
11.4 Company D
- 11.4.1 Business Overview
- 11.4.2 Product Portfolio
- 11.4.3 Business Strategies
- 11.4.4 SWOT Analysis
- 11.4.5 Major News and Events
11.5 Company E
- 11.5.1 Business Overview
- 11.5.2 Product Portfolio
- 11.5.3 Business Strategies
- 11.5.4 SWOT Analysis
- 11.5.5 Major News and Events

12 Japan Biosimilar Market - Industry Analysis

12.1 Drivers, Restraints, and Opportunities
- 12.1.1 Overview
- 12.1.2 Drivers
- 12.1.3 Restraints
- 12.1.4 Opportunities
12.2 Porters Five Forces Analysis
- 12.2.1 Overview
- 12.2.2 Bargaining Power of Buyers
- 12.2.3 Bargaining Power of Suppliers
- 12.2.4 Degree of Competition
- 12.2.5 Threat of New Entrants
- 12.2.6 Threat of Substitutes
12.3 Value Chain Analysis